Astellas Pharma Inc (ALPMY)
9.46
+0.12
(+1.28%)
USD |
OTCM |
Apr 17, 15:59
Astellas Pharma Enterprise Value: 20.90B for April 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 16, 2024 | 20.90B |
| April 15, 2024 | 20.78B |
| April 12, 2024 | 21.28B |
| April 11, 2024 | 22.60B |
| April 10, 2024 | 22.50B |
| April 09, 2024 | 22.92B |
| April 08, 2024 | 23.01B |
| April 05, 2024 | 23.16B |
| April 04, 2024 | 23.12B |
| April 03, 2024 | 23.32B |
| April 02, 2024 | 23.50B |
| April 01, 2024 | 23.46B |
| March 28, 2024 | 23.43B |
| March 27, 2024 | 23.77B |
| March 26, 2024 | 23.98B |
| March 25, 2024 | 23.70B |
| March 22, 2024 | 23.91B |
| March 21, 2024 | 24.00B |
| March 20, 2024 | 23.79B |
| March 19, 2024 | 23.66B |
| March 18, 2024 | 23.61B |
| March 15, 2024 | 23.56B |
| March 14, 2024 | 23.28B |
| March 13, 2024 | 23.32B |
| March 12, 2024 | 23.44B |
| Date | Value |
|---|---|
| March 11, 2024 | 23.68B |
| March 08, 2024 | 23.19B |
| March 07, 2024 | 23.43B |
| March 06, 2024 | 23.53B |
| March 05, 2024 | 23.52B |
| March 04, 2024 | 24.02B |
| March 01, 2024 | 24.14B |
| February 29, 2024 | 23.75B |
| February 28, 2024 | 23.84B |
| February 27, 2024 | 23.86B |
| February 26, 2024 | 23.93B |
| February 23, 2024 | 23.86B |
| February 22, 2024 | 23.80B |
| February 21, 2024 | 24.09B |
| February 20, 2024 | 24.13B |
| February 16, 2024 | 24.05B |
| February 15, 2024 | 23.96B |
| February 14, 2024 | 24.01B |
| February 13, 2024 | 23.68B |
| February 12, 2024 | 23.55B |
| February 09, 2024 | 23.50B |
| February 08, 2024 | 23.39B |
| February 07, 2024 | 23.73B |
| February 06, 2024 | 23.68B |
| February 05, 2024 | 23.87B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
20.78B
Minimum
Apr 15 2024
31.58B
Maximum
Feb 11 2020
25.79B
Average
25.66B
Median
Sep 10 2020
Enterprise Value Benchmarks
| Daiichi Sankyo Co Ltd | 48.82B |
| Takeda Pharmaceutical Co Ltd | 72.34B |
| Nxera Pharma Co Ltd | 1.010B |
| PeptiDream Inc | 1.250B |
| Stemcell Holdings Inc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 98.29M |
| Revenue (Quarterly) | 2.858B |
| Total Expenses (Quarterly) | 2.730B |
| EPS Diluted (Quarterly) | 0.0546 |
| Gross Profit Margin (Quarterly) | 82.01% |
| Profit Margin (Quarterly) | 3.44% |
| Earnings Yield | -0.09% |
| Operating Earnings Yield | 0.41% |
| Normalized Earnings Yield | -0.3933 |